Spero Therapeutics

NASDAQ: SPRO ↗$2.26 USD~$150M (small-cap) MCAP

#Antibacterial #Multidrug-Resistant Infections #Complicated UTI #Nontuberculous Mycobacterial Disease

Spero Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections. Its lead asset Utebzi (tebipenem pivoxil HBr), an oral carbapenem co-developed with GSK, was FDA-approved in June 2026 for complicated urinary tract infections.

Company Info

Sector:Biotechnology / Anti-Infectives (Antibacterial)

Headquarters:Cambridge, Massachusetts, USA

Founded:2013

Website:www.sperotherapeutics.com/

Upcoming Milestones & Key Dates

2026-07

Commercial

Utebzi commercial launch (US)

2026-Q3

Clinical

SPR720 Phase 2a readout

2026-Q4

Regulatory

SPR206 IND-enabling work continues

Clinical Development Pipeline

Utebzi (tebipenem pivoxil HBr)

Target: Oral carbapenem antibiotic

Complicated urinary tract infection (cUTI)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SPR720

Target: Oral gyrase B inhibitor

Nontuberculous mycobacterial (NTM) pulmonary disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

SPR206

Target: Next-generation polymyxin

MDR gram-negative infections

Preclinical

Phase 1

Phase 2

Phase 3

Approved

FDA approves GSK, Spero's oral treatment for complicated UTIs ↗

The FDA approved GSK and Spero Therapeutics' Utebzi (tebipenem HBr) as the first oral antibiotic for complicated urinary tract infections, ending a multi-year partnership-driven development path.

Leadership Team

Esther Rajavelu

President & CEO (Interim)

Timothy Keutzer

Chief Operating Officer

Frank E. Thomas

Board Chair

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →